(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 5.56% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Haemonetics's revenue in 2026 is $1,352,013,000.On average, 12 Wall Street analysts forecast HAE's revenue for 2027 to be $65,015,285,879, with the lowest HAE revenue forecast at $62,194,468,717, and the highest HAE revenue forecast at $68,154,582,398. On average, 12 Wall Street analysts forecast HAE's revenue for 2028 to be $68,427,564,704, with the lowest HAE revenue forecast at $64,878,794,726, and the highest HAE revenue forecast at $72,567,796,345.
In 2029, HAE is forecast to generate $72,522,299,294 in revenue, with the lowest revenue forecast at $69,701,482,132 and the highest revenue forecast at $76,071,069,272.